No Detail Found!

Factors affecting the efficacy of regorafenib in metastatic colorectal cancer: is tumour sidedness important?

Author(s)
Seher Nazli Kazaz Karadeniz Technical University,Trabzon,Turkiye
Ali Caner Ozdover Karadeniz Technical University,Trabzon,Turkiye
Nergis Usta Karadeniz Technical University,Trabzon,Turkiye
Atila Yildirim Karadeniz Technical University,Trabzon,Turkiye
Evren Fidan Karadeniz Technical University,Trabzon,Turkiye
Feyyaz Ozdemir Karadeniz Technical University,Trabzon,Turkiye
Abstract
Objective: To investigate the outcomes of regorafenib treatment in refractory metastatic colorectal cancer (mCRC) patients by primary tumour sidedness, the e ects of previously targeted therapies, RAS status and in ammatory markers. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey, between January 2012 and September 2020. Methodology: Clinical data of 102 mCRC patients treated with regorafenib were compared according to the right and left colon subgroups, in terms of factors a ecting outcomes of regorafenib treatment. Kaplan-Meier method was used to identify factors associated with the overall survival. Results: Disease control rate (DCR) with regorafenib were similar in both right and left-sided colon tumours (60%vs. 61%, respectively, p>0.99). The median overall survival (OS) was 6.6 months in patients with right-sided colon cancers and 10.1 months in patients with left-sided colon cancers, but it was not signi cant (p=0.238). When evaluating by RAS status, there was an increase in favour of the right-sided mCRC in progression-free survival and OS, without statistical signi cance. In multivariate analysis, the patients with metastatic sites <3 and the number of prior systemic therapies d3 line had signi cantly higher survival. Conclusion: The tumour burden a ected the response to regorafenib in subsequent treatments and regorafenib was also e ective in heavily treated mCRC patients. There was no di erence in PFS and OS in terms of tumour sidedness by regorafenib treatment.
Publication Details
Page(s) 659-665
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 6, Year: 2023

Request the full text from PASTIC

Keywords
colorectal cancer, Regorafenib, Tumour sidedness
0

Citations

0

Downloads

67

Views